{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:37:50Z","timestamp":1792424270008,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.autrev.2016.12.005","type":"journal-article","created":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T06:51:00Z","timestamp":1481784660000},"page":"136-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: A systematic review and meta-analysis of 21 clinical trials"],"prefix":"10.1016","volume":"16","author":[{"given":"Ting Ting","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Wen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2016.12.005_bb0005","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0270-9295(03)00049-4","article-title":"Diagnosis and natural course of membranous nephropathy","volume":"4","author":"Glassock","year":"2003","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.autrev.2016.12.005_bb0010","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.ajkd.2005.08.020","article-title":"Idiopathic membranous nephropathy: outline and rationale of a treatment strategy","volume":"46","author":"Du Buf-Vereijken","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.autrev.2016.12.005_bb0015","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJM199208273270904","article-title":"Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian idiopathic membranous nephropathy treatment study group","volume":"9","author":"Ponticelli","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2016.12.005_bb0020","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/ndt\/gfq017","article-title":"Alkylating agents in membranous nephropathy: efficacy proven beyond doubt","volume":"25","author":"Hofstra","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2016.12.005_bb0025","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/ndt\/gfh036","article-title":"Membranous nephropathy study group. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate","volume":"5","author":"Du Buf-Vereijken","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2016.12.005_bb0030","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","article-title":"Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial","volume":"4","author":"Cattran","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2016.12.005_bb0035","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000167436","article-title":"Treatment of idiopathic membranous nephropathy unresponsive to methylprednisolone and chlorambucil with cyclosporine","volume":"1","author":"DeSanto","year":"1987","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.autrev.2016.12.005_bb0040","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/ndt\/14.4.1036","article-title":"Treatment of membranous glomerulopathy with cyclosporin A: how much patience is required?","volume":"14","author":"Fritsche","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2016.12.005_bb0045","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004293.pub3","article-title":"Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome","volume":"10","author":"Chen","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2016.12.005_bb0050","article-title":"Immunosuppressive treatment for nephrotic idiopathic membranous nephropathy: a meta-analysis based on Chinese adults","volume":"9","author":"Xie","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2016.12.005_bb0055","article-title":"The Cochrane collaboration's tool for assessing risk of bias in randomized trials","volume":"oct182","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2016.12.005_bb0060","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3109\/08860221003728754","article-title":"Comparison of immunosuppressive therapeutic regimens in patients with nephrotic syndrome due to idiopathic membranous nephropathy","volume":"5","author":"Kosmadakis","year":"2010","journal-title":"Ren Fail"},{"key":"10.1016\/j.autrev.2016.12.005_bb0065","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000348475","article-title":"Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial","volume":"181","author":"Xu","year":"2013","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.autrev.2016.12.005_bb0070","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MAJ.0b013e3181ca3a7d","article-title":"Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial","volume":"3","author":"Chen","year":"2010","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.autrev.2016.12.005_bb0075","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/nep.12569","article-title":"Tacrolimus combined with corticosteroids versus modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial","volume":"2","author":"Ramachandran","year":"2016","journal-title":"Nephrology"},{"key":"10.1016\/j.autrev.2016.12.005_bb0080","first-page":"522","article-title":"Comparison on the therapeutic effect of cyclosporine A and cyclophosphamide in the treatment of idiopathic membranous nephropathy","volume":"06","author":"Li","year":"2011","journal-title":"Chin J Integr Tradit West Nephrol"},{"key":"10.1016\/j.autrev.2016.12.005_bb0085","first-page":"1910","article-title":"Efficacy of cyclosporine A combined with hormone in treatment of membranous nephropathy","volume":"13","author":"Liu","year":"2013","journal-title":"Journal of Qiqihar University of Medicine"},{"key":"10.1016\/j.autrev.2016.12.005_bb0090","article-title":"Comparison on the therapeutic effect of cyclosporine A and cyclophosphamide in the treatment of idiopathic membranous nephropathy","volume":"16","author":"Chen","year":"2014","journal-title":"China Med Pharm"},{"key":"10.1016\/j.autrev.2016.12.005_bb0095","first-page":"906","article-title":"Comparison on the therapeutic effect of cyclosporine A and cyclophosphamide in the treatment of idiopathic membranous nephropathy","volume":"10","author":"Li","year":"2011","journal-title":"Chin J Integr Tradit West Nephrol"},{"key":"10.1016\/j.autrev.2016.12.005_bb0100","first-page":"2467","article-title":"The analysis of short and long term clinical efficacy of cyclosporine and hormone in the treatment of patients with idiopathic membranous nephropathy","volume":"16","author":"Liu","year":"2015","journal-title":"Chin J Prim Med Pharm"},{"key":"10.1016\/j.autrev.2016.12.005_bb0105","first-page":"716","article-title":"Clinical effect of cyclophosphamide or tacrolimus combined with glucocorticoids in the treatment of idiopathic membranous nephropathy","volume":"08","author":"Xie","year":"2014","journal-title":"Chin J Integr Tradit West Nephrol"},{"key":"10.1016\/j.autrev.2016.12.005_bb0110","first-page":"3238","article-title":"Comparison of the effects of two therapeutic regimen in the treatment of idiopathic membranous nephropathy","volume":"21","author":"Ding","year":"2014","journal-title":"Chin J Prim Med Pharm"},{"key":"10.1016\/j.autrev.2016.12.005_bb0115","first-page":"1674","article-title":"The efficacy of tacrolimus in the treatment of idiopathic membranous nephropathy","volume":"10","author":"Chen","year":"2009","journal-title":"The Journal of practical Medicine"},{"key":"10.1016\/j.autrev.2016.12.005_bb0120","series-title":"Clinical effects of tacrolimus division combined with glucocorticoids on the treatment of idiopathic membranous nephropathy","author":"Li","year":"2013"},{"key":"10.1016\/j.autrev.2016.12.005_bb0125","first-page":"69","article-title":"Clinical effect of tacrolimus combined with glucocorticoids in the treatment of idiopathic membranous nephropathy","volume":"31","author":"Hou","year":"2014","journal-title":"China Med Herald"},{"key":"10.1016\/j.autrev.2016.12.005_bb0130","series-title":"Tacrolimus combined with low-dose prednisone in treatment of nephrotic idiopathic membranous nephropathy","author":"Shen","year":"2012"},{"key":"10.1016\/j.autrev.2016.12.005_bb0135","first-page":"797","article-title":"Efficacy and safety of tacrolimus versus cyclosporine in adults with idiopathic membranous nephropathy","volume":"7","author":"Li","year":"2012","journal-title":"Chin J Clin Pharmacol Ther"},{"key":"10.1016\/j.autrev.2016.12.005_bb0140","first-page":"90","article-title":"Observation on the clinical effect of tacrolimus in the treatment of idiopathic membranous nephropathy","volume":"5","author":"Ye","year":"2014","journal-title":"Journal of Clinical Medicine in Practice"},{"key":"10.1016\/j.autrev.2016.12.005_bb0145","first-page":"115","article-title":"Medium dose of tacrolimus for idiopathic membranous nephropathy","volume":"01","author":"Wu","year":"2011","journal-title":"China Pharm"},{"key":"10.1016\/j.autrev.2016.12.005_bb0150","first-page":"121","article-title":"Clinical observation of cyclophosphamide combined with glucocorticoid on membranous nephropathy","volume":"01","author":"Zhang","year":"2016","journal-title":"Chin J Biochem Pharm"},{"key":"10.1016\/j.autrev.2016.12.005_bb0155","first-page":"2181","article-title":"Prognosis of tacrolimus combined with prednisone on patients with idiopathic membranous nephropathy","volume":"22","author":"Zhou","year":"2015","journal-title":"Chin J Clin Pharmacol"},{"key":"10.1016\/j.autrev.2016.12.005_bb0160","series-title":"The long-term efficacy and safety study of tacrolimus combined with corticosteroids in the treatment of idiopathic membranous nephropathy","author":"Xu","year":"2015"},{"key":"10.1016\/j.autrev.2016.12.005_bb0165","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jfma.2015.07.021","article-title":"Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy","volume":"1","author":"Peng","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.autrev.2016.12.005_bb0170","first-page":"584","article-title":"Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria","volume":"4","author":"Li","year":"2008","journal-title":"J Nephrol"},{"key":"10.1016\/j.autrev.2016.12.005_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106164","article-title":"The calcineurin inhibitor tacrolimus reduces proteinuria in membranous nephropathy accompanied by a decrease in angiopoietin-like-4","volume":"9","author":"Peng","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2016.12.005_bb0180","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrneph.2009.101","article-title":"Controversies in the treatment of idiopathic membranous nephropathy","volume":"5","author":"Waldman","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.autrev.2016.12.005_bb0185","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/ndt\/gfr220","article-title":"Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of evidence-based therapy","volume":"27","author":"Mcquarrie","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2016.12.005_bb0190","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1681\/ASN.V72290","article-title":"Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy","volume":"2","author":"Ambalavanan","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2016.12.005_bb0195","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1093\/ndt\/gfl360","article-title":"Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome","volume":"21","author":"Alexopoulos","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2016.12.005_bb0200","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.ki.5002215","article-title":"Grupo Espa\u00f1ol de Estudio de la Nefropat\u00eda Membranosa. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial","volume":"71","author":"Praga","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2016.12.005_bb0205","article-title":"Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology","volume":"78","author":"Ankivell","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.autrev.2016.12.005_bb0210","first-page":"560","article-title":"Effective treatment administration of cyclophosphamide in membranous nephropathy","volume":"4","author":"Dede","year":"2008","journal-title":"J Nephrol"},{"key":"10.1016\/j.autrev.2016.12.005_bb0215","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1440-1797.2010.01427.x","article-title":"Treatment of nephrotic idiopathic membranous nephropathy with monthly i.v. pulse cyclophosphamide and oral steroids: a single center's retrospective study","volume":"16","author":"Yuan","year":"2011","journal-title":"Nephrology"},{"key":"10.1016\/j.autrev.2016.12.005_bb0220","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/qjmed\/91.5.359","article-title":"Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency","volume":"91","author":"Branten","year":"1998","journal-title":"QJM"},{"key":"10.1016\/j.autrev.2016.12.005_bb0225","doi-asserted-by":"crossref","first-page":"438","DOI":"10.7326\/0003-4819-116-6-438","article-title":"Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The glomerular disease collaborative network","volume":"116","author":"Falk","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2016.12.005_bb0230","first-page":"139","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"2","author":"KDIGO Glomerulonephritis Work Group","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2016.12.005_bb0235","first-page":"467","article-title":"2014 expert consensus on immunosuppressive treatment for Chinese adults with nephrotic syndrome","volume":"6","author":"Immunosuppressive Treatment for Chinese Adults with Nephrotic Syndrome Work Group","year":"2014","journal-title":"Clin J Nephrol"},{"key":"10.1016\/j.autrev.2016.12.005_bb0240","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1053\/j.ajkd.2008.11.033","article-title":"Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial","volume":"5","author":"Choudhry","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.autrev.2016.12.005_bb0245","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00467-012-2228-3","article-title":"Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome","volume":"11","author":"Wang","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.autrev.2016.12.005_bb0255","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0197-2456(97)00024-X","article-title":"Strengths and limitations of meta-analysis: larger studies may be more reliable","volume":"16","author":"Flather","year":"1997","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.autrev.2016.12.005_bb0260","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1002\/sim.1096","article-title":"Meta-analyses in systematic reviews of randomized controlled trials in perinatal medicine: comparison of fixed and random effects models","volume":"20","author":"Villar","year":"2001","journal-title":"Stat Med"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997216302713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997216302713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T08:53:36Z","timestamp":1658048016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997216302713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1568997216302713"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2016.12.005","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: A systematic review and meta-analysis of 21 clinical trials","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2016.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}